

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

**(1) RESIGNATION OF A DIRECTOR
AND
(2) PROPOSED APPOINTMENT OF A DIRECTOR**

(1) RESIGNATION OF A DIRECTOR

The Company announced that the Board has accepted the resignation of Mr. Ou Linfeng, a non-executive Director with effect from 9 August 2016.

(2) PROPOSED APPOINTMENT OF A DIRECTOR

The Board proposed to appoint Mr. Liu Renmu as a non-executive Director for a term commencing on the date of approval by the Shareholders and expiring on 31 December 2016.

Notice for convening the EGM containing details of the proposed appointment will be dispatched to the Shareholders as soon as practicable.

(1) RESIGNATION OF A DIRECTOR

Mr. Ou Linfeng (“**Mr. Ou**”) tendered a written notice to resign as a non-executive Director of the Company due to his busy schedule and increasing commitments in other business which make him no longer possible to spend sufficient time on the business of the Company.

Mr. Ou has confirmed that he has no disagreement with the Board and there are no other matters that should be brought to the attention of the Shareholders or the Stock Exchange in relation to his resignation.

The Board would like to express its sincere gratitude to Mr. Ou for his valuable contributions to the Company during his tenure of service.

(2) PROPOSED APPOINTMENT OF A DIRECTOR

Due to the resignation of Mr. Ou as aforesaid, the Board proposes to appoint Mr. Liu Renmu (“**Mr. Liu**”) as a non-executive Director for a term commencing on the date of approval by the Shareholders at the EGM and expiring on 31 December 2016.

PARTICULARS OF THE PROPOSED DIRECTOR

General Information

Mr. Liu Renmu, aged 52, graduated from the University of California in the United States of America, majoring in marketing, and obtained a bachelor’s degree granted by the business school of the University of California, Los Angeles in June 1993. Mr. Liu has been engaged in education and marketing industry for 20 years, with a wealth of marketing experience in education market.

Mr. Liu worked as a sales manager of Jare Auto Inc. (United States) from 1991 to 1995. He was the chairman of the board and chief executive officer of Han Sheng international Inc. (瀚聖國際股份有限公司) from 1997 to 1999 and of Wei Han Internet Limited by Share Ltd. (威瀚資訊網路股份有限公司) from 2000 to 2010. From 2003 to 2008, he was an executive director of Kishow Inc. (力瀚文創股份有限公司). From 2005 to 2008, Mr. Liu served as a committee member of the science and education research center of Taiwan Yuan Ze University. He was the chairman of the board of Beijing Daren Technology Inc. (北京大仁科技股份有限公司) from 2004 to 2011. Since 2011, Mr. Liu has served as the executive director of marketing of Inland Empire Renewable Energy Regional Center (United States).

(i) The Emolument of the Director

The proposed emolument of Mr. Liu is RMB40,000 per annum during his term of service which will be paid in proportion to the actual length of service starting from the date of appointment.

The proposed emolument of Mr. Liu is determined on the basis of prevailing market rate, scope of work, level of involvement, experience, seniority and the recommendation of the remuneration committee of the Company.

(ii) Service Agreement of the proposed Director

Mr. Liu will enter into a service agreement with the Company after the proposed ordinary resolutions regarding his appointment being passed at the EGM. The newly appointed non-executive Director will be for a term commencing on the date of approval by Shareholders at the EGM and expiring on 31 December 2016.

Save as disclosed above, Mr. Liu does not hold any other position with the Company or other members of the Group nor does he have any relationship with any other directors, supervisor, senior management, substantial shareholders or controlling shareholders of the Company or any of their associates (as defined in the GEM Listing Rules).

Save as disclosed above, Mr. Liu does not hold any shares, underlying shares or debentures of the Company and its associated corporations which are required to be disclosed under Part XV of the SFO.

In addition, Mr. Liu does not hold any position in other companies listed on the Stock Exchange or any other securities market for the last three years and does not have any other major appointments or professional qualifications.

The Board is not aware of any other matter which has to be brought to the attention of holders of securities of the Company in respect of the proposed change of Director nor is there any other information required to be disclosed pursuant to the requirements as set out in Rule 17.50(2) of the GEM Listing Rules.

EXTRAORDINARY GENERAL MEETING

According to the Articles of Association of the Company, the proposed appointment of Mr. Liu is subject to the approval by the Shareholders by way of ordinary resolutions at EGM.

Notice for convening the EGM containing details of the relevant resolutions will be dispatched to the Shareholders as soon as practicable.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise.

“Board”	the board of Directors (including the independent non-executive directors)
“Company”	天津泰達生物醫學工程股份有限公司 (Tianjin TEDA Biomedical Engineering Company Limited), a joint stock company established in the PRC with limited liability on 8 September 2000 whose H shares are listed and traded on GEM (Stock Code: 8189)
“Director(s)”	director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be convened
“GEM”	the Growth Enterprise Market of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC

“SFO”	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong)
“Shareholder(s)”	shareholder(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
9 August 2016

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Wang Shuxin; the non-executive Directors of the Company are Feng Enqing and Chen Yingzhong; the independent non-executive Directors of the Company are Guan Tong, Wu Chen and Peter K.S. Chan.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain on the GEM website at <http://www.hkgem.com> on the Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.